Bal Pharma share price & results
- Jun 2026
- Jun 2026
Fully integrated pharma manufacturer of bulk APIs/intermediates and finished-dosage formulations, among the largest producers/exporters of Gliclazide, with herbal (Bal Vedics) and institutional product lines
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 88.4 | +34.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 9.0 | −0.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.2 | +262.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 9.05 | −1.9 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 2.46 | +2.1 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 13.52 | +13.6 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −0.9% 1Y
1Y: ₹83.76 on 24 Oct 2025 → ₹83.04. High ₹114.45 (9 Sept 2026), low ₹60.42 (30 Mar 2026).
- Previous close
- ₹79.1
- Market cap
- ₹170 Cr
- 52-week range
- ₹60.42 – ₹114.45
- One year
- +1.37%
- Price to earnings (TTM to Jun 2026)
- 23.48×
- Return on equity (TTM to Jun 2026)
- 9.05%
Overview
- Symbol
- NSE:BALPHARMA
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Bal Pharma Limited does
Based on the company's own presentations, annual report and earnings calls.
Bal Pharma Limited manufactures Active Pharmaceutical Ingredients (APIs) and pharma intermediates as well as finished dosage formulations (FDFs) such as tablets, capsules, syrups, IV infusions, ophthalmic and cream/ointment preparations, across therapeutic areas including anti-diabetes, anti-histamine, anti-inflammatory, cardiology and dermatology. It runs six manufacturing units across Karnataka, Maharashtra, Uttarakhand and Rajasthan, selling APIs and formulations domestically through its own field-force/distributor network and brands (Diabend, Glyduz, Servetus, Vibrant, Lifezen) and exporting under its own brand names or via registered third-party sellers and institutional/government tenders.
Segments
- API / Intermediates
- Finished Dosage Formulations (FDF)
- Herbal (Bal Vedics)
- Institutional Sales
- OTC (Lifezen)
- Manufacturing facilities
- 6 (3 API/Intermediates + 3 FDF, across Karnataka, Maharashtra, Uttarakhand & Rajasthan; one FDF unit non-operational, held for strategic purpose)
- API/Intermediates installed capacity
- 370 tonnes per annum
- FDF installed capacity
- ~3 billion tablets + 490 million capsules + 10 million creams/tubes per annum
- API/Intermediates portfolio
- 22+ active molecules
- Finished dosage formulations portfolio
- 200+ formulations across 20 therapeutic segments
- Employee strength
- 1000+
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +262% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 75 | 73 | 82 | 66 | 74 | 87 | 84 | 88 |
| Expenses | 67 | 65 | 74 | 59 | 68 | 78 | 73 | 80 |
| Operating profit | 7 | 8 | 8 | 6 | 6 | 10 | 11 | 8 |
| Operating margin | 10.0% | 10.9% | 9.6% | 9.4% | 7.8% | 11.1% | 12.7% | 9.0% |
| Other income | 0 | 1 | 1 | 1 | 1 | 0 | -0 | 0 |
| Interest | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 |
| Depreciation | 2 | 3 | 2 | 3 | 2 | 3 | 3 | 3 |
| Profit before tax | 2 | 1 | 3 | 0 | 1 | 2 | 3 | 1 |
| Tax rate | 21.1% | 5.4% | −99.3% | 0.0% | 0.0% | 0.0% | −11.8% | 0.0% |
| Net profit | 1 | 1 | 6 | 0 | 1 | 2 | 4 | 1 |
| EPS (₹ per share) | 0.75 | 0.43 | 3.52 | 0.20 | 0.49 | 1.22 | 2.32 | 0.73 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 339 | 303 | 311 |
| Expenses | 307 | 273 | 279 |
| Operating profit | 32 | 30 | 32 |
| Other income | 3 | 2 | 2 |
| Interest | 15 | 17 | 17 |
| Depreciation | 9 | 9 | 11 |
| Profit before tax | 11 | 6 | 6 |
| Net profit | 9 | 8 | 7 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 15 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 72 | 80 | 77 | 83 | 62 | 88 |
| Borrowings | 98 | 125 | 134 | 145 | 155 | 154 |
| Other liabilities | 104 | 126 | 108 | 107 | 116 | 133 |
| Total liabilities | 290 | 348 | 334 | 351 | 349 | 391 |
| Fixed assets | 53 | 63 | 79 | 87 | 92 | 94 |
| Capital work in progress | 1 | 0 | 0 | 3 | 3 | 7 |
| Investments | 8 | 8 | 9 | 5 | 0 | 4 |
| Other assets | 227 | 276 | 245 | 256 | 253 | 285 |
| Total assets | 290 | 348 | 334 | 351 | 349 | 391 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 10 | 31 | 5 | 29 | 20 | 30 |
| Cash from investing | -7 | -13 | -22 | -19 | -15 | -21 |
| Cash from financing | -3 | -17 | 17 | -7 | -8 | -10 |
| Net cash flow | 0 | 0 | 0 | 3 | -2 | 0 |
| Free cash flow | 7 | 23 | -9 | 18 | 2 | 8 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 102 | 101 | 114 | 110 | 114 | 113 |
| Inventory days | 146 | 162 | 210 | 167 | 238 | 269 |
| Days payable | 118 | 158 | 195 | 148 | 189 | 206 |
| Cash conversion cycle | 130 | 105 | 129 | 129 | 163 | 176 |
| Working capital days | 62 | 61 | 61 | 32 | 29 | 30 |
| Return on capital employed | 13.0% | 12.0% | 10.0% | 11.0% | 10.0% | 9.0% |
| Dividend payout | 16.0% | 17.0% | 26.0% | 25.0% | 24.0% | 28.0% |
Ownership
Who owns it
Promoters hold 50.87% as of Jun 2026; institutions added 0.01 pts since Mar 2026.
- Promoters 50.87%
- Foreign institutions 0.15%
- Domestic institutions 0.00%
- Public 48.99%
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 12.64% held
The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Bal Pharma Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 17.24% | unchanged | |
| 12.64% | newly disclosed | |
| 6.59% | unchanged | |
| 3.44% | −0.21 pp | |
| 3.31% | unchanged | |
| 3.30% | unchanged | |
| 3.06% | unchanged | |
| 2.98% | unchanged | |
| 1.88% | unchanged | |
| 1.88% | unchanged | |
| 1.84% | unchanged | |
| 1.79% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Bal Pharma Limited
Free account: one company. Everything above stays public.
Write why you follow Bal Pharma Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Bal Pharma Limited
Guides on how to read this kind of business and the numbers that matter.